2 results
Approved WMORecruitment started
We aim to investigate in an RCT the (cost-)effectiveness of CM, compared with usual care CBT in the treatment of CUD in youths aged 16 to 22 years. Both outpatient treatments are provided for 12 weeks.PRIMARY STUDY QUESTION:1. What is the efficacy…
Approved WMORecruiting will start
To utilize the therascreen KRAS RGQ PCR Kit, as a screening test in Amgen*s Phase 3 Clinical Study Protocol 20210081, in order to identify patients with mCRC KRAS G12C mutation positive tumors to be enrolled in the drug clinical trial. Results of…